Literature DB >> 27913672

First model of dimeric LRRK2: the challenge of unrevealing the structure of a multidomain Parkinson's-associated protein.

Giambattista Guaitoli1,2, Bernd K Gilsbach1, Francesco Raimondi3, Christian Johannes Gloeckner1,2.   

Abstract

Mutations within the leucine-rich repeat kinase 2 (LRRK2) gene represent the most common cause of Mendelian forms of Parkinson's disease, among autosomal dominant cases. Its gene product, LRRK2, is a large multidomain protein that belongs to the Roco protein family exhibiting GTPase and kinase activity, with the latter activity increased by pathogenic mutations. To allow rational drug design against LRRK2 and to understand the cross-regulation of the G- and the kinase domain at a molecular level, it is key to solve the three-dimensional structure of the protein. We review here our recent successful approach to build the first structural model of dimeric LRRK2 by an integrative modeling approach.
© 2016 The Author(s); published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  cross-linking; leucine-rich repeat kinase; modeling; structure

Mesh:

Substances:

Year:  2016        PMID: 27913672     DOI: 10.1042/BST20160226

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  3 in total

Review 1.  "LRRK2: Autophagy and Lysosomal Activity".

Authors:  Marta Madureira; Natalie Connor-Robson; Richard Wade-Martins
Journal:  Front Neurosci       Date:  2020-05-25       Impact factor: 4.677

2.  The Michael J. Fox Foundation's Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease.

Authors:  Shalini Padmanabhan; Brian K Fiske; Marco A S Baptista
Journal:  Cells       Date:  2020-08-11       Impact factor: 6.600

Review 3.  LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease.

Authors:  Shirley Yin-Yu Pang; Rachel Cheuk Nam Lo; Philip Wing-Lok Ho; Hui-Fang Liu; Eunice Eun Seo Chang; Chi-Ting Leung; Yasine Malki; Zoe Yuen-Kiu Choi; Wing Yan Wong; Michelle Hiu-Wai Kung; David Boyer Ramsden; Shu-Leong Ho
Journal:  Transl Neurodegener       Date:  2022-01-31       Impact factor: 8.014

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.